NCT04158310View on ClinicalTrials.gov

Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children

UnknownOBSERVATIONAL
Enrollment

9,207

Participants

Timeline

Start Date

November 11, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

March 1, 2021

Conditions
Community Acquired Pneumonia
Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY

NCT04158310 - Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children | Biotech Hunter | Biotech Hunter